---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-303251"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:26:58.353985+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences & GSK collaborate on oligonucleotide drugs; $170M upfront, up to $3.3B milestones

## Summary
- Upfront payment: $170M ($120M cash + $50M equity investment at $4.68/share, a 15% premium to 30-day VWAP).
- Total eligible milestones up to $3.3B: WVE-006 ($225M dev/launch + $300M commercial); 8 GSK programs (up to $1.2B + $1.6B).
- GSK gets exclusive global license to WVE-006, a preclinical RNA editing candidate for alpha-1 antitrypsin deficiency.
- Wave leads preclinical research for all programs; GSK takes over at IND-enabling for its programs. Wave leads first-in-patient for WVE-006.
- Cash runway extended into 2025; deal expected to close in Q1 2023 pending HSR antitrust clearance.

## SEC filing metadata
- accession: 0001193125-22-303251
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312522303251/0001193125-22-303251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312522303251/d432281d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-303251
- JSON: https://secwatch.observer/filing/0001193125-22-303251.json
- Plain text: https://secwatch.observer/filing/0001193125-22-303251.txt

## Key facts
- Material Agreements
  Wave Life Sciences Ltd. entered into Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) ("GSK") valued at $170 million (effective 2022-12-13).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: GlaxoSmithKline Intellectual Property (No. 3) ("GSK")
  - Value: $170 million
  - Effective: 2022-12-13
  source text: On December 13, 2022, Wave Life Sciences USA, Inc. and Wave Life Sciences UK Limited (collectively, “ Wave ”), each direct, wholly-owned subsidiaries of Wave Life Sciences Ltd. (the “ Company ”) entered into a Collaboration and License Agreement (the “ Collaboration Agreement ”) with GlaxoSmithKline Intellectual Property (No. 3) (“ GSK ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312522303251/0001193125-22-303251-index.htm
- Material Agreements
  Wave Life Sciences Ltd. entered into Share Purchase Agreement with Glaxo Group Limited ("GGL") valued at approximately $50 million (effective 2022-12-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Glaxo Group Limited ("GGL")
  - Value: approximately $50 million
  - Effective: 2022-12-13
  source text: In connection with the parties’ entry into the Collaboration Agreement, the Company has agreed to sell to Glaxo Group Limited (“ GGL ”), an affiliate of GSK, 10,683,761 ordinary shares, no par value (the “ Ordinary Shares ”), for aggregate cash consideration of approximately $50 million, or $4.68 per Ordinary Share (the “ Equity Investment ”), pursuant to the terms of a Share Purchase Agreement, dated December 13, 2022, by and between GGL and the Company (the “ Share Purchase Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312522303251/0001193125-22-303251-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.